Pharmacogenomics of Hypertension and Heart Disease

Current Hypertension Reports

Volumn 17, Issue 9, 2015, Pages

  Arwood, Meghan J ^a,c   Cavallari, Larisa H ^b   Duarte, Julio D ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

Clopidogrel; Hypertension; Pharmacogenetics; Simvastatin; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CLOPIDOGREL; DILTIAZEM; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL; WARFARIN; ANTIHYPERTENSIVE AGENT;

ADRB1 GENE; AFRICAN AMERICAN; ANTIHYPERTENSIVE ACTIVITY; ATRIAL FIBRILLATION; CAUCASIAN; CHINESE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; GENE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY TUBULE ABSORPTION; NEDD4L GENE; PHARMACOGENOMICS; PRACTICE GUIDELINE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; VALIDATION PROCESS; YEATS4 GENE; ANIMAL; COMPLICATION; GENETICS; HEART DISEASES; PHARMACOGENETICS; PROCEDURES; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HEART DISEASES; HUMANS; HYPERTENSION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84939222746     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0586-5     Document Type: Review

References (96)

1. CDC, NCHS. Underlying cause of death 1999–2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999–2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program (2015). Accessed 1 Mar 2015.
2. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):434–41. doi:10.1161/CIR.0000000000000157.
4. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13):914–21. doi:10.1056/NEJM199304013281303.
5. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24(5):336–44. doi:10.1038/jhh.2009.76.
6. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165(8):923–8. doi:10.1001/archinte.165.8.923.
7. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8. doi:10.1016/S0140-6736(08)60655-8.
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
9. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012;44 Suppl 1:S17–22. doi:10.3109/07853890.2011.653399.
10. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.1001/jama.2013.284427.
11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1097/01.hjh.0000431740.32696.cc.
12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. doi:10.1016/j.jacc.2013.05.019.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. doi:10.1093/eurheartj/ehs104.
14. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749–67. doi:10.1161/CIR.0000000000000095.
15. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344–426. doi:10.1161/CIR.0000000000000134.
16. Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296.
17. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–7. doi:10.1038/clpt.2010.279.
18. Relling MV. Personalized medicines using genome wide approaches—not really. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 6, 2015; New Orleans, Louisiana.
19. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-Dehoff RM, et al. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012;10:47. doi:10.1186/1479-5876-10-47.
20. Ritchie MD. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum Genet. 2012;131(10):1615–26. doi:10.1007/s00439-012-1221-z.
21. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74(1):44–52. doi:10.1016/S0009-9236(03)00068-7.
22. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006;80(1):23–32. doi:10.1016/j.clpt.2006.03.004.
23. Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens. 2011;29(2):388–95. doi:10.1097/HJH.0b013e3283410390.
24. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013;31(4):698–704. doi:10.1097/HJH.0b013e32835e2a71.
25. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008;52(2):359–65. doi:10.1161/HYPERTENSIONAHA.107.104273.
26. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J. 2013;13(3):257–63. doi:10.1038/tpj.2012.4.
27. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther. 2011;89(3):366–78. doi:10.1038/clpt.2010.315.
28. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84(6):715–21. doi:10.1038/clpt.2008.139.
29. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, et al. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension. 2013;62(1):48–54. doi:10.1161/HYPERTENSIONAHA.111.00823.
30. Rossier BC, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annu Rev Physiol. 2002;64:877–97. doi:10.1146/annurev.physiol.64.082101.143243.
31. Park JH, Roeder RG. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol Cell Biol. 2006;26(11):4006–16. doi:10.1128/MCB.02185-05.
32. Schulze JM, Wang AY, Kobor MS. YEATS domain proteins: a diverse family with many links to chromatin modification and transcription. Biochem Cell Biol. 2009;87(1):65–75. doi:10.1139/O08-111.
33. Yu Z, Kong Q, Kone BC. Aldosterone reprograms promoter methylation to regulate alphaENaC transcription in the collecting duct. Am J Physiol Renal Physiol. 2013;305(7):F1006–13. doi:10.1152/ajprenal.00407.2013.
34. Bubien JK. Epithelial Na+ channel (ENaC), hormones, and hypertension. J Biol Chem. 2010;285(31):23527–31. doi:10.1074/jbc.R109.025049.
35. Schild L. The epithelial sodium channel and the control of sodium balance. Biochim Biophys Acta. 2010;1802(12):1159–65. doi:10.1016/j.bbadis.2010.06.014.
36. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, et al. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015. doi:10.1097/HJH.0000000000000541.
37. Hong KW, Go MJ, Jin HS, Lim JE, Lee JY, Han BG, et al. Genetic variations in ATP2B1, CSK, ARSG and CSMD1 loci are related to blood pressure and/or hypertension in two Korean cohorts. J Hum Hypertens. 2010;24(6):367–72. doi:10.1038/jhh.2009.86.
38. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990–4. doi:10.1038/40187.
39. Shahnin MH, Rotroff DM, Gong Y, Langaee TY, McDonough CW, Beitelshees AL, et al. Integrating metabolomics and genomics reveals novel biomarkers of hydrochlorothiazide response in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. [abstract]. Clin Pharmacol Ther. 2015;97(S1):S11. The authors took a unique approach, where genomics, metabolomics, and transcriptomics were integrated to identify novel biomarkers of HCTZ response.
40. Pushkin A, Carpenito G, Abuladze N, Newman D, Tsuprun V, Ryazantsev S, et al. Structural characterization, tissue distribution, and functional expression of murine aminoacylase III. Am J Physiol Cell Physiol. 2004;286(4):C848–56. doi:10.1152/ajpcell.00192.2003.
41. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, et al. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015;4(1), e001521. doi:10.1161/JAHA.115.001778. This is the only GWAS of antihypertensive drug response to utilize a double-blind, placebo-controlled cross-over study where each participant received four different classes of antihypertensives, each as monotherapy, in a randomized order.
42. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350(2):151–62. doi:10.1016/j.mce.2011.07.034.
43. Frau F, Zaninello R, Salvi E, Ortu MF, Braga D, Velayutham D, et al. Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics. 2014;15(13):1643–52. doi:10.2217/pgs.14.119. This GWAS of antihypertensive drug response identified a newly discovered variant, rs10752271, in the CAMK1D gene that was associated with SBP reduction to losartan. This was validated in silico in the GENRES cohort.
44. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J. 2013;13(5):430–6. doi:10.1038/tpj.2012.34.
45. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genomics. 2013;23(12):697–705. doi:10.1097/FPC.0000000000000012.
46. Gong Y, McDonough CW, Beitelshees AL, Karnes JH, O’Connell JR, Turner ST, et al. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014;34(2):123–30. doi:10.1002/phar.1355.
47. Magnusson Y, Levin MC, Eggertsen R, Nystrom E, Mobini R, Schaufelberger M, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78(3):221–31. doi:10.1016/j.clpt.2005.06.004.
48. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52(8):644–51. doi:10.1016/j.jacc.2008.05.022.
49. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288–93. doi:10.1073/pnas.0509937103.
50. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013;6(1):137–43. doi:10.1161/CIRCEP.111.969618.
51. Aleong RG, Sauer WH, Sauer WH, Murphy GA, Port JD, Anand IS, et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta(1)389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013;1(4):338–44. doi:10.1016/j.jchf.2013.04.002.
52. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54(5):432–44. doi:10.1016/j.jacc.2009.05.009.
53. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14(5):510–7. doi:10.1038/nm1750.
54. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3(1):21–8. doi:10.1161/CIRCHEARTFAILURE.109.885962.
55. Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacol Res:Off J Ital Pharmacol Soc. 2014;88:99–106. doi:10.1016/j.phrs.2013.12.002.
56. Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin Pharmacol Ther. 2014;95(3):281–93. doi:10.1038/clpt.2013.234.
57. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–99. doi:10.1056/NEJMoa0801936.
58. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–8. doi:10.1038/clpt.2014.125.
59. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165(6):1008–14. doi:10.1016/j.ahj.2013.01.025.
60. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–16. doi:10.1016/j.jacc.2009.04.053.
61. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502(7471):377–80. doi:10.1038/nature12508.
62. Floyd JS, Bis JC, Brody JA, Heckbert SR, Rice K, Psaty BM. GATM locus does not replicate in rhabdomyolysis study. Nature. 2014;513(7518):E1–3. doi:10.1038/nature13629.
63. Luzum JA, Kitzmiller JP, Isackson PJ, Ma C, Medina MW, Dauki AM, et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case–control analysis of 715 dyslipidemic individuals. Cell Metab. 2015;21(4):622–7. doi:10.1016/j.cmet.2015.03.003.
64. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):199S–233S. doi:10.1378/chest.08-0672.
65. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. doi:10.1056/NEJMoa010746.
66. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–21. doi:10.1016/S0140-6736(05)67660-X.
67. Steinhubl SR, Berger PB, Mann 3rd JT, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–20.
68. Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(5):923–33. doi:10.1111/j.1538-7836.2010.03809.x.
69. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62. doi:10.1056/NEJMoa0809171.
70. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30. doi:10.1001/jama.2010.1543.
71. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23. doi:10.1038/clpt.2013.105.
72. Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C: Semin Med Genet. 2014;166C(1):56–67. doi:10.1002/ajmg.c.31390.
73. Lieb W, Volzke H, Pulley JM, Roden DM, Kroemer HK. Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther. 2012;92(4):443–5. doi:10.1038/clpt.2012.119.
74. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O’Neill C, et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C: Semin Med Genet. 2014;166C(1):76–84. doi:10.1002/ajmg.c.31396.
75. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95. doi:10.1038/clpt.2011.371.
76. Lee JA, Lee CR, Reed BN, Plitt DC, Polasek MJ, Howell LA, et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics. 2015;16(4):303–13. doi:10.2217/pgs.14.180.
77. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006;95(2):253–9. doi:10.1267/THRO06020253.
78. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, et al. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013;167(6):2882–8. doi:10.1016/j.ijcard.2012.07.020.
79. Sanchez-Borges M, Acevedo N, Vergara C, Jimenez S, Zabner-Oziel P, Monzon A, et al. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol. 2009;19(5):375–82.
80. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113(4):771–5. doi:10.1016/j.jaci.2003.12.323.
81. Lewis JP, Ryan K, O’Connell JR, Horenstein RB, Damcott CM, Gibson Q, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013;6(2):184–92. doi:10.1161/CIRCGENETICS.111.964627.
82. Li Q, Chen BL, Ozdemir V, Ji W, Mao YM, Wang LC, et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007;8(6):577–86. doi:10.2217/14622416.8.6.577.
83. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005;95(6):805–8. doi:10.1016/j.amjcard.2004.11.045.
84. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–8.
85. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72(6):702–10. doi:10.1067/mcp.2002.129321.
86. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312–21. doi:10.1038/sj.clpt.6100290.
87. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):459–64. doi:10.1038/clpt.2009.223.
88. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112(4):1013–21. doi:10.1182/blood-2008-03-144899.
89. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–9. doi:10.1038/clpt.2011.185.
90. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87(5):572–8. doi:10.1038/clpt.2010.13.
91. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2015;25(2):73–81. doi:10.1097/FPC.0000000000000108.
92. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303. doi:10.1056/NEJMoa1311386.
93. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93. doi:10.1056/NEJMoa1310669.
94. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 2012;12(5):417–24. doi:10.1038/tpj.2011.18.
95. Nutescu EDJ, Cheng W, Sarangpur S, Gor D, Drozda K, Galanter W, et al. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. Circulation. 2014;130, A16119.
96. Aslibekyan S, Claas SA, Arnett DK. To replicate or not to replicate: the case of pharmacogenetic studies: establishing validity of pharmacogenomic findings: from replication to triangulation. Circ Cardiovasc Genet. 2013;6(4):409–12. doi:10.1161/CIRCGENETICS.112.000010.